Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
- PMID: 32830877
- DOI: 10.1111/jdv.16752
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
Abstract
Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States.
Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus.
Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.
© 2020 European Academy of Dermatology and Venereology.
Comment in
-
Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab.J Am Acad Dermatol. 2021 Jul;85(1):e47-e48. doi: 10.1016/j.jaad.2021.03.018. Epub 2021 Mar 10. J Am Acad Dermatol. 2021. PMID: 33713786 No abstract available.
-
Pemphigus management guidelines: A life-saving perspective.J Am Acad Dermatol. 2021 Jul;85(1):e45-e46. doi: 10.1016/j.jaad.2021.01.105. Epub 2021 Mar 10. J Am Acad Dermatol. 2021. PMID: 33713787 No abstract available.
References
-
- Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet Lond Engl 2019; 394: 882-894.
-
- Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011; 29: 432-436.
-
- Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 2011; 9: 844-856; quiz 857.
-
- Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 2011; 9: 927-947.
-
- Kasperkiewicz M, Ellebrecht CT, Takahashi H et al. Pemphigus. Nat Rev Dis Primer 2017; 3: 17026.